Brief: Astrana Health Inc Q2 Revenue USD 631.442 Million Vs. IBES Estimate USD 638.3 Million

Astrana Health

07/08/2025 21:06

Overview

Astrana Q2 2025 revenue rises 35% yr/yr but misses analyst expectations, per LSEG data

Adjusted EBITDA for Q2 at higher end of co's guidance

Company completed acquisition of Prospect Health, enhancing growth prospects

Outlook

Astrana sees Q3 revenue between $925 mln and $965 mln

Company expects full-year revenue between $3.1 bln and $3.3 bln

Astrana anticipates Q3 adjusted EBITDA of $65 mln to $70 mln

Company reiterates full-year guidance including Prospect Health acquisition

Result Drivers

REVENUE GROWTH - Total revenue increased by 35% year-over-year, driven by effective management of medical cost trends

TECHNOLOGY PLATFORM - Company's technology-enabled model contributed to strong results, providing real-time visibility into patient health

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$631.44 mln
$638.30 mln (9 Analysts)
Q2 Income from Operations
$49.68 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for Astrana Health Inc is $46.00, about 52.6% above its August 6 closing price of $21.81

The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 21 three months ago

Press Release: ID:nPn2rdyrwa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)